Orca Bio Announces $250M Raise as First Cell Therapy Nears Approval

Orca Bio has raised $250 million across two equity financing rounds as it prepares for the potential commercialisation of its lead cell therapy, with regulatory approval anticipated in early 2026.

The capital was raised across a previously undisclosed Series E round completed in 2024 and a Series F financing that closed in December 2025, according to the company. An Orca spokesperson said the amounts raised in each round were broadly comparable.

In addition to the equity financing, the company secured access to up to $100 million in debt financing through a credit facility provided by Silicon Valley Bank.

The combined financing is intended to support commercial readiness, manufacturing scale-up and pipeline development as the company moves towards its first potential product launch.

Founded in 2016 and based in Menlo Park, Orca Bio is developing high-precision cell therapies, with its most advanced programme, Orca-T, targeting patients with blood cancers undergoing bone marrow transplantation. The company completed a Phase 3 clinical study last year, reporting improved outcomes in patients with acute leukaemia.

Beyond Orca-T, Orca Bio is advancing additional cell therapy programmes and exploring applications in autoimmune diseases, as well as approaches that could allow the use of cells from non-matching donors.

Sources:
Orca Bio
Business Wire
Fierce Pharma
Business Journals
FinSMEs

Image source:
Lightspeed Venture Partners

J.V.